4.8 Article

A vein bypass first versus a best endovascular treatment first revascularisation strategy for patients with chronic limb threatening ischaemia who required an infra-popliteal, with or without an additional more proximal infra-inguinal revascularisation procedure to restore limb perfusion (BASIL-2): an open-label, randomised, multicentre, phase 3 trial

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Surgery

Procedural and 12-month in-hospital costs of primary infrapopliteal bypass surgery, infrapopliteal best endovascular treatment, and major lower limb amputation for chronic limb threatening ischemia

Matthew A. Popplewell et al.

Summary: Chronic limb-threatening ischemia (CLTI) is a global issue due to tobacco use and diabetes prevalence. The study compared the costs and effectiveness of primary infrapopliteal vein bypass surgery (BS), best endovascular treatment (BET), and major limb major amputation (MLLA) over a 12-month period, with BET being the most cost-effective option.

JOURNAL OF VASCULAR SURGERY (2022)

Article Medicine, General & Internal

Surgery or Endovascular Therapy for Chronic Limb-Threatening Ischemia

Alik Farber et al.

Summary: In patients with chronic limb-threatening ischemia (CLTI), it is uncertain whether endovascular therapy or surgical revascularization is superior for improving limb outcomes. This international trial enrolled 1830 patients with CLTI and peripheral artery disease, and found that surgical revascularization was more effective than endovascular therapy in reducing major adverse limb events or death in patients with an adequate great saphenous vein for surgery.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Review Surgery

Quality of Life in Chronic Limb Threatening Ischaemia: Systematic Review and Meta-Analysis

Leonard L. Shan et al.

Summary: This study aimed to compare the effectiveness of revascularization, major lower extremity amputation (MLEA), and conservative management (CM) in patients with chronic limb threatening ischaemia (CLTI) by assessing the temporal changes in quality of life (QoL). The findings suggested that revascularization may provide modest QoL benefits, while MLEA or CM can maintain QoL. However, the certainty of evidence is generally low and further standardization of QoL studies is needed.

EUROPEAN JOURNAL OF VASCULAR AND ENDOVASCULAR SURGERY (2022)

Article Surgery

Prediction Models for Two Year Overall Survival and Amputation Free Survival After Revascularisation for Chronic Limb Threatening Ischaemia

Tetsuro Miyata et al.

Summary: This study created prediction models for two year overall survival and amputation free survival after revascularisation in patients with chronic limb threatening ischaemia. These models showed good discrimination and can assist in determining treatment strategies and risk adjustment for quality benchmarking.

EUROPEAN JOURNAL OF VASCULAR AND ENDOVASCULAR SURGERY (2022)

Article Surgery

Factors associated with delays in revascularization in patients with chronic limb-threatening ischaemia: population-based cohort study

P. Birmpili et al.

Summary: This study identified several factors associated with delays in revascularization for patients with CLTI in the UK, with the weekday of admission being the most notable factor. The results support the argument for vascular units to have resources for a 7-day service.

BRITISH JOURNAL OF SURGERY (2021)

Article Surgery

Survival prediction in patients with chronic limb-threatening ischemia who undergo infrainguinal revascularization

Jessica P. Simons et al.

EUROPEAN JOURNAL OF VASCULAR AND ENDOVASCULAR SURGERY (2019)

Article Surgery

Global Vascular Guidelines on the Management of Chronic Limb-Threatening Ischemia

Michael S. Conte et al.

EUROPEAN JOURNAL OF VASCULAR AND ENDOVASCULAR SURGERY (2019)

Editorial Material Surgery

Global Vascular Guidelines for patients with critical limb-threatening ischemia

Peter F. Lawrence et al.

JOURNAL OF VASCULAR SURGERY (2019)

Article Cardiac & Cardiovascular Systems

Nitinol Stent Versus Bypass in Long Femoropopliteal Lesions 2-Year Results of a Randomized Controlled Trial

Florian K. Enzmann et al.

JACC-CARDIOVASCULAR INTERVENTIONS (2019)